AstraZeneca says COVID-19 antibody therapy neutralized Omicron in FDA study
AstraZeneca (AZN) announced that the company’s recently authorized COVID-19 antibody therapy Evusheld retained its neutralizing effect against the newly-detected Omicron variant of...
seekingalpha.com
why?
2021.12.16 - [(국내) 제약&바이오/기업 관련 이슈] - 삼바 소식
삼바 소식
※ 기업 개요 참고 2021.11.07 - [(국내) 제약&바이오/종목 분석] - 2022 관심종목 스터디 -1-; (207940)삼성바이오로직스, (000100)유한양행 2022 관심종목 스터디 -1-; (207940)삼성바이오로직스, (000100)유한..
jerry-stories.tistory.com
위 글에서 삼바가 장기지속형 코로나19 항체복합제 'AZD7442'를 생산하고 있다고 했습니다.
아래는 기사 내용입니다.
AstraZeneca says COVID-19 antibody therapy neutralized Omicron in FDA study
- AstraZeneca (AZN +1.7%) announced that the company’s recently authorized COVID-19 antibody therapy Evusheld retained its neutralizing effect against the newly-detected Omicron variant of the coronavirus.
- The Anglo-Dutch pharma giant cited preclinical data to note that the neutralizing potency of Evusheld — measured using Inhibitory Concentration 50 (IC50) — stood at 171 ng/ml and 277 ng/ml in two confirmatory tests. The findings were within the neutralizing antibody levels of a person who was previously infected with COVID-19, the company said. Meanwhile, IC50 of Evusheld against the original strain of the virus stood at nearly 1.3 ng/ml and 1.5 ng/ml, respectively.
- The research was done by investigators at the FDA’s Center for Biologics Evaluation and Research with the support of funding from the U.S. government.
- The results of the treatment’s effect on Omicron have come only a few days after the FDA authorized Evusheld — a long-acting antibody combination of tixagevimab and cilgavimab — as a preventative treatment for COVID-19.
댓글